We are live on ! Find out more
FCMI

Foresite Capital Management III Portfolio holdings

AUM $37.9M
1-Year Est. Return 6.87%
This Fund
S&P 500
This Quarter Est. Return
+21.59%
1 Year Est. Return
-6.87%
3 Year Est. Return
+444.07%
5 Year Est. Return
+547.28%
10 Year Est. Return
–
AUM
$86M
AUM Growth
-$48.3M
Cap. Flow
-$58.6M
Cap. Flow %
-68.15%
Top 10 Hldgs %
100%
Holding
10
New
–
Increased
2
Reduced
1
Closed
2

Top Buys

Rank Stock Value
1
KYNB
Kyntra Bio
KYNB
+$5.6M
2
ACRS icon
Aclaris Therapeutics
ACRS
+$3.95M

Top Sells

Rank Stock Value
1
MYOK
MyoKardia, Inc. Common Stock
MYOK
+$54.4M
2
VRNA
Verona Pharma
VRNA
+$6.93M
3
NTRA icon
Natera
NTRA
+$6.81M

Sector Composition

Rank Sector Weight
1 Healthcare 80.45%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
XLRN
1
DELISTED
Acceleron Pharma
XLRN
$13.9M 16.15%
108,630
– –
NTRA icon
2
Natera
NTRA
$36.5B
$12.7M 14.73%
127,305
-81,463
-39% -$6.81M
KYNB
3
Kyntra Bio
KYNB
$29M
$11.3M 13.18%
12,231
+5,331
+77% +$5.6M
EPZM
4
DELISTED
Epizyme, Inc
EPZM
$10.8M 12.6%
998,278
– –
ACRS icon
5
Aclaris Therapeutics
ACRS
$744M
$10.5M 12.18%
1,620,244
+935,332
+137% +$3.95M
CBAY
6
DELISTED
Cymabay Therapeutics
CBAY
$9.42M 10.95%
1,641,804
– –
NVAX icon
7
Novavax
NVAX
$1.22B
$558K 0.65%
5,000
– –
VRNA
8
DELISTED
Verona Pharma
VRNA
– –
-1,111,112
Closed -$6.93M
MYOK
9
DELISTED
MyoKardia, Inc. Common Stock
MYOK
– –
-399,360
Closed -$54.4M

Similar funds

PIM
Ponoi II Management San Francisco, California $38.3M AUM 32.02% 1-Year Est. Return
KCGDR
Kiron Capital Gestao de Recursos Sao Paulo, Brazil $36.9M AUM 49.85% 1-Year Est. Return
SEM
Spectrum Equity Management San Francisco, California $39.1M AUM 63.69% 1-Year Est. Return
ALFIA
Accel Leaders Fund II Associates Palo Alto, California $36.6M AUM 58.14% 1-Year Est. Return
MCMI
Matrix China Management III Grand Cayman, Cayman Islands $39.3M AUM
LCM
LH Capital Markets New York $39.4M AUM 14.61% 1-Year Est. Return
HLC
Hunt Lane Capital New York $39.6M AUM 58.74% 1-Year Est. Return
KXA
KPCB XV Associates Menlo Park, California $35.8M AUM 57.59% 1-Year Est. Return

Foresite Capital Management III's Q4 2020 Portfolio in Review

As of Q4 2020, Foresite Capital Management III held 10 positions worth $86M, down 36% from $134M the previous quarter. Its ten largest holdings account for 100% of the portfolio.

Foresite Capital Management III withdrew a net $58.6M in Q4 2020, closing 2 positions and reducing 1 holding. Its most notable exit was MyoKardia, Inc. Common Stock, an estimated $54.4M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 80% of assets, down from 91% a quarter earlier.

Against the trend, Foresite Capital Management III added an estimated $5.6M to Kyntra Bio.

  • Foresite Capital Management III added most to Kyntra Bio in Q4 2020, an estimated $5.6M increase.
  • Foresite Capital Management III's biggest Q4 2020 reduction was Natera, cutting an estimated $6.81M.
  • Foresite Capital Management III fully exited MyoKardia, Inc. Common Stock in Q4 2020, selling an estimated $54.4M.
  • Foresite Capital Management III's ten largest holdings make up 100% of its $86M portfolio in Q4 2020.
  • Foresite Capital Management III opened 0 new positions and closed 2 in Q4 2020.
  • Foresite Capital Management III's portfolio value fell 36% quarter-over-quarter to $86M.

Based on Foresite Capital Management III's 13F filing for Q4 2020, filed 16 Feb 2021.